Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target

Molecular Cancer Therapeutics

Volumn 11, Issue 3, 2012, Pages 775-781

  Collins, Colin C ^a   Volik, Stanislav V ^a   Lapuk, Anna V ^a   Wang, Yuwei ^a,b   Gout, Peter W ^b   Wu, Chunxiao ^a   Xue, Hui ^a,b   Cheng, Hongwei ^a,b   Haegert, Anne ^a   Bell, Robert H ^a   Brahmbhatt, Sonal ^a   Anderson, Shawn ^a   Fazli, Ladan ^a   Hurtado Coll, Antonio ^a   Rubin, Mark A ^c   Demichelis, Francesca ^c   Beltran, Himisha ^c   Hirst, Martin ^b   Marra, Marco ^b   Maher, Christopher A ^d   Chinnaiyan, Arul M ^d   Gleave, Martin ^a   Bertino, Joseph R ^e   Lubin, Martin ^f   Wang, Yuzhuo ^a,b   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; ADENOSINE DERIVATIVE; BICALUTAMIDE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GOSERELIN; METHYLTHIOADENOSINE; TIOGUANINE; UNCLASSIFIED DRUG;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOME 9P; CONTROLLED STUDY; DRUG EFFECT; ENZYME DEFICIENCY; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENCY; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; SEQUENCE ANALYSIS; TUMOR XENOGRAFT;

AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DEOXYADENOSINES; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEUROENDOCRINE TUMORS; PROSTATIC NEOPLASMS; PURINE-NUCLEOSIDE PHOSPHORYLASE; SEQUENCE ANALYSIS, DNA; THIOGUANINE; THIONUCLEOSIDES; TREATMENT OUTCOME; URETHRAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859414102     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0826     Document Type: Article

References (41)

1. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992;70:254-68.
2. Abbas F, Civantos F, Benedetto P, Soloway MS. Small cell carcinoma of the bladder and prostate. Urology 1995;46:617-30.
3. Randolph TL, Amin MB, Ro JY, Ayala AG. Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance. Mod Pathol 1997;10:612-29. (Pubitemid 27293503)
4. Erasmus CE, Verhagen WI, Wauters CA, van Lindert EJ. Brain metastasis from prostate small cell carcinoma: not to be neglected. Can J Neurol Sci 2002;29:375-7. (Pubitemid 35440091)
5. Miyoshi Y, Uemura H, Kitami K, Satomi Y, Kubota Y, Hosaka M. Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU Int 2001;88:982-3. (Pubitemid 34099032)
6. Tanaka M, Suzuki Y, Takaoka K, Suzuki N, Murakami S, Matsuzaki O, et al. Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 2001;8:431-6; discussion 437.
7. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20:3072-80. (Pubitemid 34791096)
8. Spieth ME, Lin YG, Nguyen TT. Diagnosing and treating small-cell carcinomas of prostatic origin. Clin Nucl Med 2002;27:11-7. (Pubitemid 34016897)
9. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999;39:135-48.
10. Bonkhoff H. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate Suppl 1998;8:18-22. (Pubitemid 28347991)
11. Helpap B. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract. Cancer 2002;95:1415-20.
12. Moore SR, Reinberg Y, Zhang G. Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy. Urology 1992;39: 411-6.
13. Bertino JR, Waud WR, Parker WB, Lubin M. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies. Cancer Biol Ther 2011;11:627-32.
14. Marce S, Balague O, Colomo L, Martinez A, Holler S, Villamor N, et al. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. Clin Cancer Res 2006;12:3754-61. (Pubitemid 44000257)
15. Lubin M, Lubin A. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. PLoS One 2009;4:e5735.
16. Krasinskas AM, Bartlett DL, Cieply K, Dacic S. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol 2010;23:531-8.
17. Basu I, Cordovano G, Das I, Belbin TJ, Guha C, Schramm VL. A transition state analogue of 5′-methylthioadenosine phosphorylase induces apoptosis in head and neck cancers. J Biol Chem 2007; 282:21477-86. (Pubitemid 47099931)
18. Basu I, Locker J, Cassera MB, Belbin TJ, Merino EF, Dong X, et al. Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5′-methylthioadenosine phosphorylase. J Biol Chem 2011;286:4902-11.
19. Christopher SA, Diegelman P, Porter CW, Kruger WD. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16 (cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res 2002;62:6639-44. (Pubitemid 35364132)
20. Kirovski G, Stevens AP, Czech B, Dettmer K, Weiss TS, Wild P, et al. Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5′-deoxy-5′- methylthioadenosine (MTA). Am J Pathol 2011;178:1145-52.
21. Clurman BE, Groudine M. The CDKN2A tumor-suppressor locus-a tale of two proteins. N Engl J Med 1998;338:910-2. (Pubitemid 28135972)
22. Huang HY, Li SH, Yu SC, Chou FF, Tzeng CC, Hu TH, et al. Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors. Clin Cancer Res 2009;15:6963-72.
23. Behrmann I, Wallner S, Komyod W, Heinrich PC, Schuierer M, Buettner R, et al. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol 2003;163:683-90. (Pubitemid 36909429)
24. KindlerHL, BurrisHAIII, Sandler AB, Oliff IA. A phase IImulticenter study of L-alanosine, a potent inhibitor ofadenine biosynthesis, inpatients with MTAP-deficient cancer. Invest New Drugs 2009;27:75-81.
25. Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, Goetz L, et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005;64:149-59. (Pubitemid 40791764)
26. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, et al. Insulin receptor expression by human prostate cancers. Prostate 2009;69:33-40.
27. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-13.
28. Li H, Ruan J, Durbin R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res 2008;18:1851-8.
29. Zhao J, Grant SF. Advances in whole genome sequencing technology. Curr Pharm Biotechnol 2011;12:293-305.
30. Lin D, Watahiki A, Bayani J, Zhang F, Liu L, Ling V, et al. ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. Cancer Res 2008;68:4352-9.
31. Tung WL, Wang Y, Gout PW, Liu DM, Gleave M. Use of irinotecan for treatment of small cell carcinoma of the prostate. Prostate 2011;71:675-81.
32. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, et al. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 2005;85:1392-404. (Pubitemid 41509387)
33. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008;8:24-36.
34. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559-65.
35. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
36. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-54. (Pubitemid 44323701)
37. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39. (Pubitemid 37204044)
38. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 2005;96:48-55. (Pubitemid 39612416)
39. Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, et al. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res 2006;12:4043-54. (Pubitemid 44078092)
40. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010;17:535-46.
41. Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res 2011;17:783-91.